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Aims: Glycated haemoglobin (HbA1C) has been suggested to replace glucose tests in identi-
fying diabetes and pre-diabetes. We assessed agreement between fasting plasma glucose
(FPG) and HbA1C rapid tests in classifying abnormal glucose regulation (AGR), and their
utility for preventive screening in rural Africa.
Methods: A population-based survey of 795 people aged 35–60 years was conducted in a
mainly rural district in Uganda. FPG was measured using On-Call1 Plus glucometers, and
classified using World Health Organization (WHO) and American Diabetes Association
(ADA) criteria. HbA1C was measured using A1cNow
1 kits and classified using ADA criteria.
Body mass index and blood pressure were measured. Percentage agreement between the
two tests was computed.
Results: Using HbA1C, 11.3% of participants had diabetes compared with 4.8% for FPG.
Prevalence of HbA1C-defined pre-diabetes (26.4%) was 1.2 times and 2.5 times higher than
FPG-defined pre-diabetes using ADA (21.8%) and WHO (10.1%) criteria, respectively. With
FPG as the reference, agreement between FPG and HbA1C in classifying diabetes status was
moderate (Kappa = 22.9; Area Under the Curve (AUC) = 75%), while that for AGR was low
(Kappa = 11.0; AUC = 59%). However, agreement was high (over 90%) among negative tests
and among participants with risk factors for type 2 diabetes (obesity, overweight or
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Conclusions: Although low in the general sample, agreement between HbA1C and FPG is
excellent among persons who test negative with either test. A single test can therefore
identify the majority at lower risk for type 2 diabetes. Nurses if trained can conduct these
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Identifying individuals with abnormal glucose regulation
(AGR) enables intensified preventive measures to be invoked
earlier and evidence shows that it is cost-effective [1–3]. Type 2
diabetes and pre-diabetes are detected through an oral glucose
tolerance test (OGTT), fasting plasma glucose (FPG) or glycated
haemoglobin (HbA1C). Diagnostic cut-offs for these tests
have been defined by the World Health Organization (WHO)
and the American Diabetes Association (ADA) [4,5]. However,
the debate about affordable but valid diagnostics for early
detection of high risk persons at primary care levels in low
income countries continues.
While the OGTT is the more sensitive test [6], it has a
lengthy cumbersome procedure, poor reproducibility, and
questionable cost-effectiveness [6–8]. FPG is easier, cheaper
and more reproducible, but has lower sensitivity and high
pre-analytical variability (4–14%) [9]. In 2009, experts from
the ADA, the European Association for the Study of Diabetes,
and the International Diabetes Federation recommended
that HbA1C should be the primary test for early detection of
type 2 diabetes and pre-diabetes in asymptomatic persons
[4]. In 2011, WHO too recommended that HbA1C is useful for
diabetes screening, ‘provided there is stringent quality
assurance and standardization’ [10]. HbA1C does not require
fasting, its analytical variability is less than 2%, and it is
relatively stable over 2–3 months [9,11]. However, it is costly
[7] and is affected by haemolysis, haemoglobinopathies,
triglycerides, and common drugs like Aspirin [9,12]. Evidence
of its value in detection of pre-diabetes is also inconclusive
[10].
Pre-diabetes is now defined by three criteria: impaired
glucose tolerance (determined by the OGTT), impaired fasting
glucose (determined by FPG) and HbA1C levels between 5.7 and
6.4% (39–46 mmol/mol). Likewise, each of these tests has cut-
off point for diagnosis of diabetes. The challenge is their level
of agreement: While many studies have demonstrated that
both FPG and HbA1C have a high validity [9,11,13,14], there is
limited data on their level of agreement in classification of
both diabetes and AGR, feasibility of their use by primary care
workers, and their utility in screening for high risk persons at
primary care facilities.
Type 2 diabetes is on the rise in low income countries [15].
However, akin to most low income countries, Uganda’s policy
and strategy for non-communicable disease (NCD) preven-
tion is new and evolving [16]. Uganda’s only official guidelines
for type 2 diabetes were published in 1998 [17]. These
guidelines focus on management of symptomatic persons
in secondary care settings with no guidance on preventive
screening.The main objective of this study was to assess the level of
agreement between FPG and HbA1C rapid tests in defining
diabetes and AGR, factors that enhance their agreement, their
utility in preventive screening, and whether primary care
workers can perform them. We analyze the implications of
using either test in detection of high risk persons at in a low
income setting.
2. Materials and methods
2.1. Setting
The Iganga-Mayuge Health and Demographic Surveillance Site
(HDSS) where this study was conducted is located in eastern
Uganda, about 120 km east of Kampala the capital city. The
HDSS has a population of approximately 70,000. It has
65 villages of which 13 are peri-urban and 52 are rural.
Surveillance data is collected every 6 months on socio-
demographic characteristics, births, deaths, and migrations.
Add-on studies are also often conducted within the HDSS,
including our study. Data for this study were collected over 8
weeks in March and April 2012.
2.2. Study population
This study was nested into a larger survey that assessed
prevalence of diabetes and pre-diabetes among people
aged 35–60 years in the HDSS [18]. The study population
comprised men and women aged 35–60 years. A multi-stage
design was used: Forty-two villages (8 peri-urban and 34 rural)
were randomly selected, from which a sample of 1656
participants was taken proportionate to the village popula-
tions. From the HDSS database, participants from each village
were selected using simple random sampling with the help of
Microsoft Excel. HDSS locator information was used to trace
participants to their households by Village Scouts who
routinely register vital events.
The sample size required for comparing differences in
prevalence of AGR as detected by FPG and HbA1C was
determined, using the formula for comparative studies by
Fleiss et al. [19]. At a significance level of 95%, power of 80%,
estimated occurrence of AGR in the general population being
3% [20], and hypothesized difference in prevalence of AGR
between the two tests at 3%, the minimum computed sample
size was 792 respondents for either comparison group. This
was adjusted to 879 respondents to cater for about 10%
estimated non-response. For this sub-study therefore, a sub-
sample of 879 of the 1656 participants in the larger study was
selected by taking a simple random sample from the master
database, assisted by Stata 10 (refer to Fig. 1)
n=1,656; participated in the study on 
prevalence of overweight and 
hypertension and associated socio-
behavioural factors; all were eligible to 
participate in the diabetes prevalence study
n=1,497; accepted to participate in 
diabetes prevalence study
n=879; Sub-sample selected to 
undergo both FPG and HBA1C 
tests
n=795; accepted to 
undergo both FPG and 
HBA1C tests
Fig. 1 – Flow-chart showing how the study sample was
obtained.
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Data for this study were collected in three stages: In stage one,
participants underwent physical measurements of height,
weight, and blood pressure. In the second stage, participants
underwent tests to assess their blood sugar status. In the third
stage, research assistants were asked about their experiences
in applying the two tests to assess the tests’ feasibility in this
setting. Data were collected by 12 teams, each having two
experienced research assistants: a nurse and a social worker.
Research assistants underwent a 5 days’ training and practice
session supervised by a laboratory technician. All measure-
ments were conducted at the participants’ homes.
2.3.1. Stage 1: physical measurements
Detailed procedures for measurement of the physical char-
acteristics have already been described elsewhere [18]. Height
was measured using standard height metres, with the
participant standing upright. Weight was measured using
calibrated Seca1 scales, with the participant lightly clothed.
BMI was calculated as weight-in-kilograms divided by the
square of height in metres. A participant was classified as
overweight if their BMI was 25 kg/m2 or greater, and obese if
their BMI was 30 kg/m2 or greater.
Two blood pressure (BP) measurements were taken
(5–30 min apart), with the participant seated, using a cali-
brated electronic BP device (Welch-Allyn1). The mean of these
two measurements was taken as their BP. Participants were
classified as having hypertension if their average systolic BP
was 140 mmHg or higher, or if their average diastolic BP was
90 mmHg or higher, or if they were on treatment for
hypertension [21].
2.3.2. Stage 2: assessment of blood sugar levels
Each participant was contacted on the day prior to their
scheduled date for data collection and an appointmentwas sought for the following day. To obtain an FPG,
they were requested not to eat anything on the appointment
day until their blood test had been conducted. All appoint-
ments were set in the morning hours before 10.30 am
and because of this, each data collection team covered
only four households per-day. Participants who reported
to have eaten anything on the appointment day were
rescheduled.
For each consenting participant two blood drops were
obtained from a finger prick using an automated lancing
device and each was placed on a separate applicator. One
sample was analyzed for plasma glucose levels using a
glucometer (On-Call Plus1, ACON Laboratories) while the
second was analyzed for HbA1C using the A1cNow
1 (Bayer)
Rapid Immuno-Assay. Both tests were in form of rapid kits.
Point-of-care (POC) tests are widely recommended for mon-
itoring of blood glucose and some brands have comparable
validity to laboratory-based tests [14,22–24]. Because of their
simple procedure, the tests were performed by the nurses on
the data collection teams.
Classification of AGR was based on the standard cut-offs
for FPG and HbA1C as defined by the ADA [4]: For FPG, (1)
participants with an FPG <5.6 mmol/l were classified as
normal; (2) participants with an FPG >6.9 mmol/l were
classified as having diabetes; (3) participants with an
FPG between 5.6 and 6.9 mmol/l were classified as having
‘pre-diabetes’. All participants with an FPG 5.6 mmol/l
were classified as having ‘AGR’. For HbA1C, (1) participants
with an HbA1C <5.7% (or <39 mmol/mol) were classified
as having normal glycosylation; (2) participants with an
HbA1C 6.5% (or 48 mmol/mol) were classified as having
diabetes; (3) participants with an HbA1C of 5.7–6.4% (39–
46 mmol/mol) were classified as having ‘pre-diabetes’. For
HbA1C, ‘AGR’ was defined as HbA1C 5.7% (or 39 mmol/
mol). ‘AGR’ therefore included both diabetes and pre-
diabetes.
Because the WHO has different cut-offs for FPG, a separate
cross-analysis between FPG and HbA1C was also conducted
using the WHO criteria, to assess whether agreement changed
significantly when WHO criteria were used compared to ADA
criteria for FPG. The WHO cut offs for FPG are as follows [5]: (1)
participants with an FPG <6.1 mmol/l were classified as
normal; (2) participants with an FPG >6.9 mmol/l were
classified as having diabetes; (3) participants with an FPG
between 6.1 and 6.9 mmol/l were classified as having ‘pre-
diabetes’. All participants with an FPG 6.1 mmol/l were
classified as having ‘AGR’.
2.3.3. Stage 3: assessing feasibility of FPG and HbA1C rapid
tests
The study nurses were interviewed as key informants. Their
experiences in using the two tests were explored. Variables
included: ease of use, challenges in the test procedure,
reversible and irreversible mistakes and device error readings
and their causes. This information was triangulated with
trainers’ observations regarding the duration of practice
sessions required for research assistants to master the
respective test procedures during their training, as well
as observational data on the actual duration of each test as
recorded during data collection.
Table 1 – Background characteristics and prevalence of
diabetes and AGR.
Characteristic n %
Sex
Males 417 52.4
Females 378 47.6
Location of residence
Rural 691 86.9
Peri-urban 104 13.1
Age-group
35–39 255 32.1
40–44 204 25.7
45–49 154 19.4
50–54 109 13.7
55–60 73 9.2
Main occupation
Subsistence farmers 500 62.9
Traders 164 20.6
Formal/salaried 39 4.9
Mechanics 92 11.6
Highest level of education
None 139 17.5
Lower primary 174 21.9
Higher primary 315 39.6
Secondary 131 16.5
Tertiary 36 4.5
Glycaemia status (FPG)
Normal 584 73.5
Pre-diabetes 173 21.8
Diabetes 38 4.8
Glycaemia status (HbA1C)
Normal 495 62.3
Pre-diabetes 210 26.4
Diabetes 90 11.3
FPG = fasting plasma glucose (using American Diabetes Associa-
tion criteria); HbA1C = glycated haemoglobin.
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Data were double entered in EpiData, cleaned and exported to
STATA10 for analysis. The percentage agreement between the
FPG and HBA1C tests in classifying diabetes and AGR was
determined at the standard cut-offs and evaluated using the
Kappa Statistic. We explored further the predictive value of
HbA1C for FPG-defined diabetes status and FPG-defined AGR.
The reason for using FPG as the reference was that our data
seems to indicate that HbA1C was the less specific one of the
two tests. Percentage agreement was also compared for the
two tests among sub-groups with risk factors for type 2 diabetes
i.e. hypertension, overweight, obesity, and a combination of
being overweight and hypertensive. Receiver operating char-
acteristic (ROC) curves were used to evaluate the performance
of HBA1C in predicting FPG-defined diabetes status and AGR.
3. Results
3.1. Background characteristics of participants
Table 1 shows the background characteristics of participants.
Of the 879 eligible participants contacted, 795 (90.4%)
participated in this study. Reasons for non-participation
included declining the blood tests (4.2%), and being away
from one’s home at 3 visits (5.4%). The majority (87%)
of participants were from the rural areas. The mean age of
participants was 43.7 years (standard deviation (SD) =6.9). The
majority (63%) were subsistence farmers. Based on FPG, 4.8%
were in the range classified as diabetes while 21.8% and 10.1%
were in the range for pre-diabetes (using ADA and WHO
criteria, respectively). Based on HbA1C, 11.3% had levels in the
range classified as diabetes while 26.4% were in the range for
pre-diabetes.
3.2. Agreement between FPG and HbA1C in classifying
diabetes status
Table 2 shows the percentage agreement between FPG and
HbA1C rapid tests in classifying diabetes status. At the cut-offs
recommended by both the WHO and ADA, overall agreement
between the two rapid tests in classifying diabetes status was
low (Kappa = 22.9). Among persons classified as having
diabetes by the FPG test, the HbA1C test provides a similar
classification for 53% of them. Likewise, among persons
classified as having diabetes by HbA1C, the FPG test only
provides a similar classification for 20% of them (Table 2).
Based on the ROC curves, the performance of HbA1C in
predicting FPG-defined diabetes status was moderate
(AUC = 0.75; 95% CI 0.65–0.85) (Fig. 2A). However, despite the
sub-optimal agreement in defining diabetes, there is high
agreement among the negatives. Among persons classified as
not having diabetes by the FPG test, the HbA1C test too
classifies 91% of them as not having diabetes. Likewise, among
persons classified as not having diabetes based on HbA1C, the
FPG test too classifies 97% of them as not having diabetes. ROC
curve analysis shows that BMI has lower but moderate
performance in predicting diabetes-defining FPG levels
(AUC = 0.66; 95% CI 0.57–0.75) (Fig. 2A).3.3. Agreement between FPG and HbA1C in classifying
abnormal glucose regulation
Table 3 shows the percentage agreement between FPG and
HbA1C rapid tests in classifying AGR. At the cut-offs recom-
mended by the WHO and ADA, respectively, agreement
between FPG and HbA1C rapid tests in classifying AGR was
very low (Kappa = 10.6% using the WHO cut-off for FPG;
Kappa = 11.0% using the ADA cut-off for FPG). However,
agreement among the negatives was good (77.4%). Based on
the ROC analysis, the performance of HbA1C in predicting FPG
defined AGR was also low (AUC = 0.59; 95% CI 0.54–0.63)
(Fig. 2B).
3.4. Agreement among participants with risk factors for
type 2 diabetes
Tables 2 and 3 show variation in percentage agreement
between both tests associated with risk factors for type 2
diabetes. Agreement between FPG and HbA1C rapid tests in
classifying diabetes status is higher when the tests are
conducted among individuals with risk factors for type 2
diabetes. While a Kappa Statistic of 22.9 is obtained when the
two tests are applied to the entire sample, a Kappa of 34.9 is
obtained for hypertensive persons, 45.4 for overweight
persons, 58.8 for persons who are both overweight and
Table 2 – Percentage agreement between FPG and HbA1C in assessing diabetes status.
HbA1C Status FPG status PPV of HBA1C for
FPG diabetes status
NPV of HBA1C for FPG
diabetes status
Percentage
Agreement
Kappa
Diabetes No diabetes
Entire sample (n = 795)
Diabetes 18 (52.6) 72 (9.5) 20.0
No diabetes 20 (47.4) 685 (90.5) 97.2 88.4 22.9
Among hypertensive persons (n = 159)
Diabetes 8 (80.0) 21 (14.1) 27.6
No diabetes 2 (20.0) 128 (85.9) 98.5 85.5 34.9
Among over-weight persons (n = 124)
Diabetes 10 (83.3) 16 (14.3) 38.5
No diabetes 2 (16.7) 96 (85.7) 98.0 85.5 45.4
Persons both overweight and hypertensive (n = 42)
Diabetes 6 (100.0) 6 (16.7) 50.0
No diabetes 0 (0.0) 30 (83.3) 100.0 85.7 58.8
Among obese persons (n = 42)
Diabetes 8 (100.0) 5 (14.7) 61.5
No diabetes 0 (0.0) 29 (85.3) 100.0 88.1 68.8
FPG = fasting plasma glucose; HbA1C = glycated haemoglobin; PPV = positive predictive value; NPV = negative predictive value.
C: Relationship between FPG-defined
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Fig. 2 – Receiver operating characteristic (ROC) curves for the relationship between FPG-defined diabetes status and
FPG-defined abnormal glucose regulation (AGR) status and HBA1C values.
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Table 3 – Percentage agreement between FPG and HBA1C in assessing abnormal glucose regulation (AGR).
Hba1c status FPG status PPV of HBA1C for IFG NPV of HBA1C for IFG Percentage agreement Kappa
Have AGR Have no AGR
Entire sample (n = 795)
Have AGR 99 (46.9) 201 (34.4) 33.0 60.6 11.0
Have no AGR 112 (53.1) 383 (65.6) 77.4
Among hypertensive persons (n = 159)
Have AGR 30 (65.2) 51 (45.1) 37.0 57.9 16.4
Have no AGR 16 (34.8) 62 (54.9) 79.5
Among over-weight persons (n = 124)
Have AGR 31 (72.1) 38 (46.9) 44.9 59.7 22.1
Have no AGR 12 (27.9) 43 (53.1) 78.2
Persons both overweight and hypertensive (n = 42)
Have AGR 15 (88.2) 16 (64.0) 40.5 57.1 21.4
Have no AGR 2 (11.8) 9 (36.0) 81.8
Among obese persons (n = 42)
Have AGR 18 (85.7) 9 (42.9) 66.7 71.4 42.9
Have no AGR 3 (14.3) 12 (57.1) 80.0
FPG = fasting plasma glucose (based on American Diabetes Association criteria); HbA1C = glycated haemoglobin; PPV = positive predictive
value; NPV = negative predictive value.
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analysis shows high performance of HbA1C in predicting
FPG-defined diabetes status among overweight persons (AUC
0.90; 95% CI 0.76–1.00) (Fig. 2C) and obese persons (AUC 0.98;
95% CI 0.94–1.00) (Fig. 2D). However, agreement between FPG
and HbA1C in classifying AGR does not improve among people
with risk factors for type 2 diabetes, except among obese
persons (Kappa = 42.9) (Table 3).
3.5. Feasibility of rapid tests in primary preventive care
According to the research assistants, the devices used in both
FPG and HbA1C measurements were easy to use, with no major
procedural challenges. They reported that with training,
nurses would be able to conduct either test. The FPG test
took a mean of four minutes to perform (including 2 min for
preparation of the sample and 2 min for the actual test). On the
other hand, the HbA1C test took a mean of nine minutes,
including four minutes for preparing the sample and five
minutes for running the test.
Challenges were observed. With regard to the FPG test,
some participants did not comply with fasting, resulting in re-
scheduling of appointments. The FPG test was also associated
with some errors from insufficient samples and not sticking to
the procedure, but these were reported to be much less
frequent compared to the HbA1C test.
The HbA1C procedure was viewed as more complicated
than the FPG procedure especially in the steps taken to prepare
the sample before running the test. As a result, HbA1C
generated more quality control errors arising from insufficient
samples and procedural mistakes than the FPG test. It also
required precise timing between steps, and a test could be
wasted by taking too long or too short between some steps.
HbA1C required longer practice before the teams could master
the steps, compared to the FPG test. The HbA1C devices failed
to operate whenever the room temperature exceeded 28 8C. In
hot climatic conditions like those in Iganga district, the HbA1C
tests must be conducted before 11.30 am on hot days. Because
of its more complicated procedures and likely errors, theHbA1C test was associated with a 10% wastage rate compared
to only 2% for the FPG test. Other causes of failure of the HbA1C
included accidental contamination with moisture and dust. By
design, the HbA1C device was tagged to only 10 tests after
which the device was auto-disabled.
4. Discussion
This analysis compares the agreement between FPG and
HbA1C rapid tests in identifying diabetes and AGR when used
in a screening strategy among 35–60 year old persons. The
setting is rural Africa, a context with very low access to
laboratories and a paucity of data on performance of
screening tests for AGR. We show that whilst overall
agreement between the two rapid tests in identifying diabetes
is moderate, and that their agreement in identifying AGR is
low, their agreement is excellent among ‘negatives’ (i.e. those
who test negative with either test), and is high in those who
have risk factors for type 2 diabetes. We also show that these
tests are feasible for use by non-physician health care
workers.
Our study finds a marked disparity in the prevalence of
diabetes and pre-diabetes between FPG and HbA1C. The
prevalence of diabetes and pre-diabetes based on HbA1C is
more than double the prevalence based on FPG. Similar
findings in which HbA1C shows a higher prevalence of diabetes
and pre-diabetes have been reported in two recent studies,
one in India [25], and another in Europe [26]. In fact, our
diabetes prevalence rate of 11.3% using HbA1C is close to that
found in India [25]. However, our findings contrast with other
studies in American, Arab and Chinese populations that show
higher prevalence of AGR with the FPG test compared to HbA1C
[27–29]. To use the rapid HbA1C as a primary care screening test
in our setting and age-group would result in a high proportion
of people classified as having diabetes or pre-diabetes,
possibly with many false positives, similar to recent observa-
tions by Nazir, Mohan and colleagues among Asian Indians
[25]. It would also have cost implications to prevention
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many high risk persons.
A possible explanation for this marked contrast in results
from the two tests is that people of African descent have
significantly higher average glycosylation of haemoglobin
than people of other origins and the differences are glucose
independent [30,31]. Several studies have indicated the need
to determine region specific cut-offs for HbA1C because of its
variation between ethnic groups due to factors that may be
genetic [1,32–36]. A second explanation for the disparity is that
the FPG test excludes some individuals with impaired glucose
tolerance and diabetes but with normal FPG. The disparity
between FPG and HbA1C may also be attributed to the age-
group in this study (35–60 years). It has been proposed that
HbA1C varies with age [33]. There is a possibility too that FPG
levels were affected by the occupational habits of the study
population, who tend to commence farming work early in the
morning. The disparity may also imply a qualitative weakness
inherent in rapid tests.
At the standard cut-offs used, the percentage agreement
between FPG and HbA1C rapid tests in classifying diabetes
status was low, while the performance of HbA1C in predicting
FPG defined diabetes status was moderate. Agreement
between the two tests in classifying AGR is even much lower.
Scho¨ttker and colleagues demonstrate similar findings among
European subjects [26]. However, Mohan and colleagues
demonstrate higher agreement when the more rigorous
quantitative laboratory tests are used, a difference that could
be attributed to inherent limitations of rapid tests [37]. The
implication of our findings is that either rapid test misses a
significant proportion of the people that would otherwise be
classified as having either diabetes or AGR by the other test.
Multiple tests are therefore necessary to increase the
diagnostic accuracy of these tests. Indeed some studies have
demonstrated that combined use of FPG with HbA1C or
random blood sugar is necessary [1,13,32,38]. There is also a
need for follow-on studies to calibrate rapid tests against the
OGTT in Africa.
However, our study also finds that while the percentage
agreement between FPG and HBA1C is low in the study sample,
agreement among the negatives (i.e. those whom either test
classifies as not having diabetes or AGR) is high. A classifica-
tion of normal glycaemia by one test is likely to be classified
similarly by the other test, suggesting that for persons who
test negative by any of these tests, one test may be sufficient
for decision-making; on the other hand, persons testing
positive by any of these tests ought to be subjected to a
confirmatory test.
Our study finds that agreement between FPG and HbA1C in
classifying diabetes status increases when the tests are
conducted among people with other risk factors for type 2
diabetes. This change is highest when the test is conducted
among obese persons (where agreement is 100% among
positives), followed by persons who are both overweight
and hypertensive (100% agreement among positives) and then
persons who are overweight (83% agreement among posi-
tives). The implication of these findings is that among obese
persons and persons who are both overweight and hyperten-
sive, rapid tests have diagnostic value for detection of
diabetes. These findings also support arguments that thepredictive value of HbA1C varies with several factors including
prevalence of diabetes [33,39].
Lastly, our study finds that in low resource settings, nurses
are able to conduct both rapid tests at point-of-care, given the
appropriate training. These findings lend credence to calls for
simplification of point-of-care diagnostics for diabetes and
AGR [22,40], and calls for task shifting of cardio-vascular risk
management to non-physician health care workers [41–43].
However, the HbA1C rapid test was more cumbersome than
the FPG test and had higher wastage rates. These limitations of
HbA1C have also been observed in other studies [39].
Our study has implications on three of six WHO health
system building blocks [44] important for integrating pre-
ventive care for type 2 diabetes in low resource settings:
diagnostics, financing and human resources. Regarding
diagnostics, our findings show that both FPG and HbA1C rapid
tests are useful for primary care level screening to detect high
risk persons, but because FPG is cheaper and has lower
wastage rates, it is the more feasible test in this setting. Since
the two tests have high agreement among people who test
negative, a single test can reliably screen out the majority
without AGR, so that lifestyle counselling is targeted to fewer
people who need it most. However, because these two tests
have low agreement among those who test positive, mechan-
isms must be put in place for confirmation of positive results,
similar to what is done in HIV testing in Africa. Other studies
are necessary to determine the most appropriate confirmatory
tests for low income settings. Financial implications may arise
from which cut-offs are used. The lower ADA cut-offs will
result in larger numbers of persons that need intervention, but
may be beneficial in detecting as many high risk persons as
possible. Regarding human resources, our findings show that
these tests can be performed by nurses if trained.
The major limitation of this study is the use of rapid point-
of-care tests rather than laboratory based tests, and therefore
could not report on sensitivity and specificity. However,
there is now sufficient evidence that some modern point-of-
care tests have comparable accuracy to laboratory based tests
[22–24]. In addition, the more cumbersome laboratory tests
would not be of value to screening in this setting. Our finding
that the two tests have high convergence among negatives
may be sufficient to defend their utility in identifying non-
high risk individuals, so that only those who test positive
with either rapid test need the more rigorous and invasive
laboratory based tests to confirm their status. Another
limitation is that the Oral Glucose Tolerance Test (OGTT)
was not performed, hence the lack of data on sensitivity and
specificity of the tests, and the exclusion of ‘impaired glucose
tolerance (IGT)’ in our comparisons. However, the OGTT
would be a very cumbersome test to apply to this number of
respondents, and has limited value in screening [1]. Another
limitation was that each participant underwent only one
round of tests, with resulting absence of data on repeatability
of the test results. However, multiple simultaneous tests are
of limited value in screening because of the cost implication.
Lastly, HbA1C is also known to be affected by haemolysis,
haemoglobinopathies like Sickle Cell disease, triglycerides,
and drugs commonly used in Africa like Aspirin and Dapsone
[9,12]. However, most of these confounders tend to lower,
rather than increase HbA1C values.
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 0 4 ( 2 0 1 4 ) 1 1 2 – 1 2 0 119We conclude that because the HbA1C and FPG rapid tests
have high agreement among people who test negative, a
single test can reliably screen out the majority without AGR,
so that lifestyle counselling is targeted. However because
their agreement among persons who test positive is low,
screening programmes should include a mechanism for
confirmation of positive test results, especially for individuals
do not have other risk factors for type 2 diabetes. While
trained nurses can use either test in clinic as well as field
surveys to identify persons with suspected diabetes and pre-
diabetes, we found FPG to be more practical than HbA1C under
field conditions.
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